newsfilter
← Latest News
GlobeNewswire·

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of targetClinical execution and data generation to support